Marx M, Levin D C
AJR Am J Roentgenol. 1986 Jul;147(1):1-8. doi: 10.2214/ajr.147.1.1.
Ischemic heart disease remains a significant cause of morbidity and mortality in the United States. Thrombolytic therapy has given physicians the capability of limiting the amount of myocardial damage that occurs when there is an acute coronary artery thrombosis and resulting myocardial infarction. This review summarizes current concepts about action mechanisms of the major thrombolytic agents, the technique and clinical results of intracoronary thrombolytic therapy, intravenous vs intracoronary administration, postthrombolytic management of underlying coronary artery disease, new agents being developed, and directions for future investigations.
在美国,缺血性心脏病仍然是发病和死亡的重要原因。溶栓治疗使医生有能力在发生急性冠状动脉血栓形成及由此导致的心肌梗死时,限制心肌损伤的程度。这篇综述总结了关于主要溶栓药物作用机制的当前概念、冠状动脉内溶栓治疗的技术和临床结果、静脉给药与冠状动脉内给药、溶栓后潜在冠状动脉疾病的管理、正在研发的新药物以及未来研究方向。